Orexigen Therapeutics Company Profile (NASDAQ:OREX)

About Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics logoOrexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:OREX
  • CUSIP: 68616410
  • Web: www.orexigen.com
Capitalization:
  • Market Cap: $44.77 million
  • Outstanding Shares: 15,227,000
Average Prices:
  • 50 Day Moving Avg: $3.04
  • 200 Day Moving Avg: $3.17
  • 52 Week Range: $1.65 - $6.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.57
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $47.82 million
  • Price / Sales: 0.94
  • Book Value: ($0.52) per share
  • Price / Book: -5.65
Profitability:
  • EBIDTA: ($157,570,000.00)
  • Net Margins: -71.59%
  • Return on Equity: -354.92%
  • Return on Assets: -29.11%
Debt:
  • Debt-to-Equity Ratio: 2.74%
  • Current Ratio: 4.17%
  • Quick Ratio: 3.81%
Misc:
  • Average Volume: 232,669 shs.
  • Beta: 2.72
  • Short Ratio: 10.41
 

Frequently Asked Questions for Orexigen Therapeutics (NASDAQ:OREX)

What is Orexigen Therapeutics' stock symbol?

Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."

How were Orexigen Therapeutics' earnings last quarter?

Orexigen Therapeutics, Inc. (NASDAQ:OREX) issued its earnings results on Tuesday, May, 9th. The company reported ($4.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.60) by $2.07. The firm earned $19.10 million during the quarter, compared to analysts' expectations of $20 million. Orexigen Therapeutics had a negative return on equity of 354.92% and a negative net margin of 71.59%. The firm's quarterly revenue was up 282.0% on a year-over-year basis. During the same period last year, the firm posted ($1.54) earnings per share. View Orexigen Therapeutics' Earnings History.

Who are some of Orexigen Therapeutics' key competitors?

Who owns Orexigen Therapeutics stock?

Orexigen Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baupost Group LLC MA (14.62%), Foresite Capital Management II LLC (4.08%), Vanguard Group Inc. (3.69%), Foresite Capital Management III LLC (2.50%), NEA Management Company LLC (2.44%) and Credit Suisse AG (1.54%). View Institutional Ownership Trends for Orexigen Therapeutics.

Who sold Orexigen Therapeutics stock? Who is selling Orexigen Therapeutics stock?

Orexigen Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG and Goldman Sachs Group Inc.. View Insider Buying and Selling for Orexigen Therapeutics.

Who bought Orexigen Therapeutics stock? Who is buying Orexigen Therapeutics stock?

Orexigen Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Foresite Capital Management III LLC, EcoR1 Capital LLC, Foresite Capital Management II LLC, Wells Fargo & Company MN, KCG Holdings Inc., Morgan Stanley and Old West Investment Management LLC. View Insider Buying and Selling for Orexigen Therapeutics.

How do I buy Orexigen Therapeutics stock?

Shares of Orexigen Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Orexigen Therapeutics stock cost?

One share of Orexigen Therapeutics stock can currently be purchased for approximately $2.94.

Analyst Ratings

Consensus Ratings for Orexigen Therapeutics (NASDAQ:OREX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Orexigen Therapeutics (NASDAQ:OREX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/16/2016Leerink SwannLower Price TargetMarket Perform$2.00 -> $1.00N/AView Rating Details
3/16/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$5.00 -> $2.00N/AView Rating Details
3/16/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
2/29/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralN/AView Rating Details
2/29/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$5.00 -> $1.00N/AView Rating Details
12/16/2015WallachBeth CapitalDowngradeBuy -> HoldN/AView Rating Details
12/12/2015Bank of America CorpReiterated RatingSellN/AView Rating Details
12/4/2015Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Orexigen Therapeutics (NASDAQ:OREX)
Earnings by Quarter for Orexigen Therapeutics (NASDAQ:OREX)
Earnings History by Quarter for Orexigen Therapeutics (NASDAQ:OREX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($2.60)($4.67)$20.00 million$19.10 millionViewListenView Earnings Details
11/3/2016Q316($2.24)$1.12$8.17 million$7.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.47)($1.73)$6.88 million$7.79 millionViewListenView Earnings Details
5/4/2016Q116($0.17)($0.15)$7.78 million$5.00 millionViewListenView Earnings Details
2/26/2016Q415($0.08)($0.12)$14.07 million$4.90 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.09)$12.17 million$10.00 millionViewListenView Earnings Details
8/6/2015Q215($0.17)($0.18)$4.92 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115($0.16)($0.14)$7.28 million$4.36 millionViewListenView Earnings Details
11/10/2014Q3($0.13)$0.09$8.93 million$30.90 millionViewListenView Earnings Details
8/7/2014Q2($0.21)($0.21)$51.80 million$0.86 millionViewListenView Earnings Details
5/8/2014Q1($0.20)($0.23)$0.93 million$0.86 millionViewListenView Earnings Details
3/12/2014Q4($0.19)($0.21)$900.00 million$857.00 millionViewListenView Earnings Details
11/12/2013Q3($0.18)($0.19)$0.80 million$0.86 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.19)($0.19)$0.90 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.44)($0.41)$0.91 million$0.86 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Orexigen Therapeutics (NASDAQ:OREX)
Current Year EPS Consensus Estimate: $-8.55 EPS
Next Year EPS Consensus Estimate: $-5.14 EPS

Dividends

Dividend History for Orexigen Therapeutics (NASDAQ:OREX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Orexigen Therapeutics (NASDAQ:OREX)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 49.65%
Insider Trades by Quarter for Orexigen Therapeutics (NASDAQ:OREX)
Institutional Ownership by Quarter for Orexigen Therapeutics (NASDAQ:OREX)
Insider Trades by Quarter for Orexigen Therapeutics (NASDAQ:OREX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Stephen A. MogliaVPSell800$1.96$1,568.00View SEC Filing  
12/2/2014Heather D TurnerSVPSell22,643$6.00$135,858.00View SEC Filing  
11/25/2014Heather D TurnerSVPSell31,388$5.83$182,992.04View SEC Filing  
11/18/2014Louis C BockDirectorBuy1,325$5.58$7,393.50View SEC Filing  
11/12/2014Louis C BockDirectorBuy27,052$5.57$150,679.64View SEC Filing  
9/22/2014Heather D TurnerVPSell300,000$4.47$1,341,000.00View SEC Filing  
9/15/2014Joseph P HaganVPBuy5,000$4.69$23,450.00View SEC Filing  
9/15/2014Michael NarachiCEOBuy50,000$4.78$239,000.00View SEC Filing  
7/31/2013Joseph P HaganInsiderSell12,000$7.80$93,600.00View SEC Filing  
7/26/2013Joseph P HaganInsiderSell10,000$7.40$74,000.00View SEC Filing  
7/25/2013Preston KlassenSVPSell71,229$7.16$509,999.64View SEC Filing  
5/28/2013Joseph P HaganInsiderSell28,000$7.00$196,000.00View SEC Filing  
5/28/2013Preston KlassenSVPSell28,771$7.21$207,438.91View SEC Filing  
1/15/2013Mark D BoothInsiderSell22,315$6.67$148,841.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Orexigen Therapeutics (NASDAQ:OREX)
Latest Headlines for Orexigen Therapeutics (NASDAQ:OREX)
Source:
DateHeadline
seekingalpha.com logoOrexigen Therapeutics (OREX) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 22 at 6:16 PM
finance.yahoo.com logoOrexigen Announces Activities at European Congress on Obesity 2017
finance.yahoo.com - May 16 at 6:47 PM
americanbankingnews.com logo-$2.40 Earnings Per Share Expected for Orexigen Therapeutics, Inc. (OREX) This Quarter
www.americanbankingnews.com - May 16 at 4:04 PM
prnewswire.com logoOrexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 - PR Newswire (press release)
www.prnewswire.com - May 11 at 7:32 PM
finance.yahoo.com logoEdited Transcript of OREX earnings conference call or presentation 9-May-17 9:00pm GMT
finance.yahoo.com - May 11 at 12:18 AM
americanbankingnews.com logoOrexigen Therapeutics, Inc. (OREX) Announces Quarterly Earnings Results, Misses Expectations By $2.07 EPS
www.americanbankingnews.com - May 10 at 7:40 PM
finance.yahoo.com logoOrexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y
finance.yahoo.com - May 10 at 11:49 AM
reuters.com logoBRIEF-Orexigen Therapeutics reports Q1 loss per share $4.67
www.reuters.com - May 9 at 6:40 PM
seekingalpha.com logoOrexigen Therapeutics, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 9 at 6:40 PM
finance.yahoo.com logoInvestor Network: Orexigen Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 6:40 PM
finance.yahoo.com logoOrexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017
finance.yahoo.com - May 9 at 6:40 PM
marketbeat.com logoOrexigen reports 1Q loss
marketbeat.com - May 9 at 5:21 PM
prnewswire.com logoOrexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch - PR Newswire (press release)
www.prnewswire.com - May 5 at 12:15 AM
finance.yahoo.com logoNavamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba® - Yahoo Finance
finance.yahoo.com - May 3 at 7:59 PM
finance.yahoo.com logoOrexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcare Conference
finance.yahoo.com - May 3 at 7:59 PM
americanbankingnews.com logoOrexigen Therapeutics (OREX) Earns Daily Media Sentiment Score of -0.11
www.americanbankingnews.com - May 3 at 9:44 AM
benzinga.com logoExclusive: Orexigen Therapeutics Execs Talk Contrave And The Stock's Roller-Coaster Ride - Benzinga
www.benzinga.com - May 2 at 4:51 PM
prnewswire.com logoOrexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for ... - PR Newswire (press release)
www.prnewswire.com - May 2 at 4:51 PM
finance.yahoo.com logoETFs with exposure to Orexigen Therapeutics, Inc. : May 2, 2017
finance.yahoo.com - May 2 at 4:51 PM
finance.yahoo.com logoOrexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries
finance.yahoo.com - May 2 at 11:10 AM
finance.yahoo.com logoNavamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba®
finance.yahoo.com - May 2 at 11:10 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: GrubHub and Orexigen Therapeutics - Yahoo Finance
finance.yahoo.com - April 28 at 8:36 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: GrubHub and Orexigen Therapeutics
finance.yahoo.com - April 28 at 8:36 AM
prnewswire.com logoResearch Reports Initiation on Drug Makers Stocks -- Depomed, Pernix Therapeutics, Orexigen Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - April 28 at 12:33 AM
prnewswire.com logoOrexigen Therapeutics Announces New Drug Submission for Contrave© in Canada - PR Newswire (press release)
www.prnewswire.com - April 28 at 12:33 AM
finance.yahoo.com logoOrexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on …
finance.yahoo.com - April 26 at 6:12 PM
americanbankingnews.com logoOrexigen Therapeutics (OREX) Receiving Somewhat Negative Media Coverage, Study Finds
www.americanbankingnews.com - April 26 at 3:02 PM
americanbankingnews.com logo Brokerages Expect Orexigen Therapeutics, Inc. (OREX) to Announce -$2.60 Earnings Per Share
www.americanbankingnews.com - April 26 at 12:03 AM
finance.yahoo.com logoOrexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on May 9, 2017
finance.yahoo.com - April 25 at 6:15 PM
finance.yahoo.com logoOrexigen Therapeutics Announces New Drug Submission for Contrave© in Canada
finance.yahoo.com - April 25 at 9:46 AM
americanbankingnews.com logoOrexigen Therapeutics (OREX) Receives News Sentiment Rating of -0.20
www.americanbankingnews.com - April 21 at 12:53 PM
finance.yahoo.com logoETFs with exposure to Orexigen Therapeutics, Inc. : April 17, 2017
finance.yahoo.com - April 17 at 6:13 PM
americanbankingnews.com logoOrexigen Therapeutics (OREX) Receiving Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 13 at 2:20 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Potential …
finance.yahoo.com - April 7 at 11:44 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 7 at 11:44 AM
finance.yahoo.com logoETFs with exposure to Orexigen Therapeutics, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 11:44 AM
americanbankingnews.com logoOrexigen Therapeutics, Inc. (OREX) Sees Large Decrease in Short Interest
www.americanbankingnews.com - April 5 at 8:27 AM
biz.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 30 at 7:20 PM
biz.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
biz.yahoo.com - March 30 at 7:20 PM
prnewswire.com logoOrexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 - PR Newswire (press release)
www.prnewswire.com - March 30 at 5:47 AM
nasdaq.com logoEarnings Reaction History: Orexigen Therapeutics, Inc., 75.0% Follow-Through Indicator, 10.3% Sensitive - Nasdaq
www.nasdaq.com - March 30 at 5:47 AM
streetinsider.com logoPre-Open Stock Movers 03/29: (EXAR) (ATHX) (VRTX) Higher; (ALQA) (PTX) (SKX) (FFIV) Lower (more...)
www.streetinsider.com - March 29 at 7:45 PM
finance.yahoo.com logoEdited Transcript of OREX earnings conference call or presentation 28-Mar-17 9:00pm GMT
finance.yahoo.com - March 29 at 9:16 AM
streetinsider.com logoAfter-Hours Stock Movers 03/28: (ATHX) (RH) (VRNT) Higher; (ALQA) (PTX) (AST) Lower (more...)
www.streetinsider.com - March 28 at 6:52 PM
reuters.com logoBRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Bruno Farmaceutici S.p.A. for Mysimba in Italy
www.reuters.com - March 28 at 6:52 PM
finance.yahoo.com logoOrexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2 …
finance.yahoo.com - March 28 at 6:52 PM
seekingalpha.com logoOrexigen Therapeutics, Inc. 2016 Q4 - Results - Earnings Call Slides
seekingalpha.com - March 28 at 6:52 PM
us.rd.yahoo.com logoOrexigen Inks Commercialization Deal for Contrave, Stock Up
us.rd.yahoo.com - March 28 at 6:52 PM
us.rd.yahoo.com logoOrexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
us.rd.yahoo.com - March 28 at 6:52 PM
biz.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
us.rd.yahoo.com - March 28 at 6:52 PM

Social

Chart

Orexigen Therapeutics (OREX) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff